Please Wait...

Hepcidin

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Hepcidin is a hormone mainly produced by hepatocytes as a precursor pro-peptide which undergoes proteolytic processing to yield its bioactive form of 25 amino-acids. Hepcidin is a key iron regulatory hormone; it inhibits iron entry into the plasma compartment by promoting the degradation of ferroportin, whose fundamental role is to release iron from tissues into the bloodstream (Nemeth et al., 2004a). Hepcidin accumulates after iron intake and under inflammatory conditions resulting in a decreased iron absorption. Conversely, Hepcidin levels drop in iron deficiency. Indeed, Hepcidin synthesis is transcriptionally regulated by the pro-inflammatory cytokine IL-6 and by iron itself resulting in a feedback regulation (Ganz and Nemeth, 2012; Nemeth et al., 2004b).

Bioclinica Lab employs a manual competitive immunoassay for the measurement of the bioactive form of Hepcidin (Hepcidin-25) in human serum.

Ganz, T., and Nemeth, E. (2012). Hepcidin and iron homeostasis. Biochim. Biophys. Acta 1823, 1434–1443.

Nemeth, E., Tuttle, M.S., Powelson, J., Vaughn, M.B., Donovan, A., Ward, D.M., Ganz, T., and Kaplan, J. (2004a). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090–2093.

Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B.K., and Ganz, T. (2004b). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113, 1271–1276.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Ck out best-of-breed trial #technologies & services: #RTSM, #esource, #EDC, site & patient #payments, global site… https://t.co/DJCNZ9C1uq
Bioclinica (20 hours ago)
ICYMI: A discussion on recently released FDA draft guidance on assessment of blood pressure response in… https://t.co/7fmrkhhuQd
Bioclinica (20 hours ago)
Our CIO & EVP Tech Gavin Nichols adds to #digitaltransformation discussion at #CMAsummit18 : W genomics & precision… https://t.co/oisqWvGJXC
Bioclinica (2 days ago)
Greetings from Tokyo where @bioclinica's Japan. China & US locations R@DrugInfoAssn DIA Japan. Discuss region-spec… https://t.co/HMzmFwA9pm
Bioclinica (4 days ago)
Reminder to join us in a live #Xtalks webinar tomorrow 11/6 on Electronic Data Capture (EDC). Everything clinical t… https://t.co/WS0L3QQnPv
Bioclinica (2 weeks ago)
Meet with representatives of Bioclinica's Japan, China & US locations at DIA Japan. Angel Y., Hidenori Seshimo & Er… https://t.co/j1alTH8oBm
Bioclinica (2 weeks ago)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner